Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

Ovidiu C. Andronesi; Isabel C. Arrillaga-Romany; K. Ina Ly; Wolfgang Bogner; Eva M. Ratai; Kara Reitz; A. John Iafrate; Jorg Dietrich; Elizabeth R. Gerstner; Andrew S. Chi; Bruce R. Rosen; Patrick Y. Wen; Daniel P. Cahill; Tracy T. Batchelor

doi:10.1038/s41467-018-03905-6

Nature Communications (Apr 2018)

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

Ovidiu C. Andronesi,
Isabel C. Arrillaga-Romany,
K. Ina Ly,
Wolfgang Bogner,
Eva M. Ratai,
Kara Reitz,
A. John Iafrate,
Jorg Dietrich,
Elizabeth R. Gerstner,
Andrew S. Chi,
Bruce R. Rosen,
Patrick Y. Wen,
Daniel P. Cahill,
Tracy T. Batchelor

Affiliations

Ovidiu C. Andronesi: Department of Radiology, Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School
Isabel C. Arrillaga-Romany: Department of Neurology, Massachusetts General Hospital, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Division of Hematology/Oncology, Harvard Medical School
K. Ina Ly: Department of Neurology, Massachusetts General Hospital, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Division of Hematology/Oncology, Harvard Medical School
Wolfgang Bogner: Department of Biomedical Imaging and Image-guided Therapy, High Field MR Centre, Medical University of Vienna
Eva M. Ratai: Department of Radiology, Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School
Kara Reitz: Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School
A. John Iafrate: Department of Pathology, Massachusetts General Hospital, Center for Integrated Diagnostics, Harvard Medical School
Jorg Dietrich: Department of Neurology, Massachusetts General Hospital, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Division of Hematology/Oncology, Harvard Medical School
Elizabeth R. Gerstner: Department of Neurology, Massachusetts General Hospital, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Division of Hematology/Oncology, Harvard Medical School
Andrew S. Chi: Brain Tumor Center, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center and School of Medicine
Bruce R. Rosen: Department of Radiology, Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School
Patrick Y. Wen: Dana-Farber Cancer Institute
Daniel P. Cahill: Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School
Tracy T. Batchelor: Department of Neurology, Massachusetts General Hospital, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Division of Hematology/Oncology, Harvard Medical School

DOI: https://doi.org/10.1038/s41467-018-03905-6
Journal volume & issue: Vol. 9, no. 1
pp. 1 – 9

Abstract

Read online

Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1) entered recently clinical trials for treatment of gliomas. Here, the authors apply a MRS imaging method for 2HG detection and assessement of the pharmacodynamic effects of the mutant IDH1 inhibitor (IDH305) in 8 mutant IDH1 glioma patients.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal